ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS

Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.